SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K, dated January 22, 2024, reports on events occurring on January 16, 2024, and January 22, 2024. SIGA Technologies, Inc. announced a significant leadership transition involving the appointment of a new Chief Executive Officer (CEO) and the retirement of the former CEO.
Key Financial Metrics and Compensation
This filing does not report operational financial metrics such as revenue, profit, cash flow, or debt. The financial data provided relates exclusively to the compensation package for the new CEO, Dr. Diem Nguyen, effective January 27, 2024:
- Base Salary: $900,000 annually, with automatic 3% increases starting in 2025.
- 2024 Bonus: $450,000 fixed annual bonus.
- Sign-On Cash Bonus: $450,000 (subject to repayment if employment ends prior to January 27, 2025, without good reason or for cause).
- Sign-On Equity Awards:
- Non-qualified stock options: $450,000 grant date value (vests 50% on each of the first two anniversaries).
- Time-based Restricted Stock Units (RSUs): $900,000 grant date value (vests one-third annually over three years).
- Performance-based RSUs (PSUs): $900,000 grant date value (vests upon achieving stock price targets of $7.00, $8.00, or $9.00).
- Additional Options: $900,000 grant date value (vests one-third annually over three years).
- Future Incentives (2025+): Target annual bonus of 50% of base salary and annual equity awards with a target value of 300% of base salary.
Material Changes
The primary material change is the executive leadership transition:
- Appointment: Dr. Diem Nguyen, Ph.D., MBA, appointed as CEO and Board member, effective January 27, 2024. She joins from Xalud Therapeutics, where she served as CEO.
- Departure: Phillip Louis Gomez, III, will retire and cease providing services effective January 26, 2024.
Outlook, Risks, and Contingencies
Employment Terms and Severance:
- Qualifying Termination (Without Cause/Good Reason): Entitles Dr. Nguyen to 2x annual base salary, the 2024 Bonus (if applicable), 12 months of COBRA, accelerated vesting of RSUs/Options, and continued vesting of PSUs.
- Change of Control: If a Qualifying Termination occurs within two years of a change of control, Dr. Nguyen is entitled to 3x the sum of base salary and bonus (2024 Bonus or Target Bonus depending on timing), 18 months of COBRA, and accelerated vesting of all equity awards.
- Performance Risk: PSUs are contingent on stock price targets; if performance goals are not met or restrictive covenants are violated, PSUs may be forfeited.
Management Commentary: The filing includes a press release (Exhibit 99.1) regarding the transition but does not provide specific operational guidance or outlook beyond the leadership change.
Investor Verification Checklist
- Verify the exact vesting schedules and performance metrics for the $2.7 million in sign-on equity awards.
- Review the full Employment Agreement (Exhibit 10.1) for specific definitions of "Good Reason" and "Cause."
- Confirm the impact of the leadership change on the company's strategic pipeline and operational continuity.
- Monitor the stock price relative to the PSU performance targets ($7.00, $8.00, $9.00) over the next 90-day periods.